Sai Life Sciences Limited has made available the recording of its earnings call for the third quarter and nine months ended December 31, 2025, providing stakeholders with comprehensive access to management discussions on the company's robust financial performance. The Hyderabad-based contract research, development and manufacturing services company continues to demonstrate strong operational excellence with significant year-on-year growth across key financial metrics.

Earnings Call Recording Now Available

Following regulatory compliance under Regulation 30 of the SEBI (LODR) Regulations, 2015, the company has uploaded the earnings call recording on its official website. The call was conducted on February 6, 2026, at 4:00 P.M. (IST), allowing management to discuss the unaudited financial results with analysts and investors.

Consolidated Performance Highlights Strong Revenue Growth

The company's consolidated performance for Q3FY26 showed impressive momentum with total revenue reaching Rs. 556 crores, representing a 27% year-on-year increase from Rs. 440 crores in Q3FY25. Net profit demonstrated exceptional growth, rising 86% year-on-year to Rs. 100 crores compared to Rs. 54 crores in the corresponding quarter last year.

EBITDA Performance Shows Operational Excellence

The company delivered outstanding EBITDA performance with EBITDA reaching Rs. 191 crores in Q3FY26, marking a substantial 54% year-on-year growth from Rs. 124 crores in Q3FY25. EBITDA margin expanded significantly to 34.4% from 28.3% in the previous year, demonstrating improved operational efficiency and cost optimization initiatives.

Nine-Month Performance Demonstrates Sustained Growth

For the nine months ended December 31, 2025, the company maintained strong momentum with total revenue of Rs. 1,590 crores, up 43% from Rs. 1,115 crores in 9MFY25. Net profit for the nine-month period surged 199% to Rs. 245 crores compared to Rs. 82 crores in the corresponding period last year.

Leadership Commentary and Strategic Vision

Managing Director and CEO Krishna Kanumuri highlighted the company's progress in building a science-led, globally relevant CRDMO through strengthened technology platforms and enhanced capabilities. He emphasized the adoption of digital, AI-enabled and modern chemistry approaches to support increasingly complex programs for global innovator clients.

Whole-time Director and CFO Siva Chittor noted the robust growth that outperformed broader CRDMO industry trends, driven by disciplined execution and healthy momentum across businesses. He confirmed that the company has invested Rs. 405 crores in capital expenditure, aligned with the long-term strategy to strengthen capabilities and expand capacity.

Sai Life Sciences has announced a strategic partnership with Mabtech to strengthen immunology research capabilities and expand service offerings in the biotechnology sector. This collaboration marks a significant step in enhancing the company's research infrastructure and global presence.

Strategic Partnership Details

The partnership between Sai Life Sciences and Mabtech focuses on boosting immunology research through combined expertise and resources. The collaboration aims to leverage both companies' strengths to deliver enhanced research capabilities and advanced scientific solutions.

Boston Laboratory Establishment

As part of this strategic initiative, Sai Life Sciences has opened a new laboratory facility in Boston, which will serve as the US hub for the Eyra platform. This expansion represents the company's commitment to strengthening its presence in the American market and providing localized services to clients.

Enhanced Service Capabilities

The partnership will enable both companies to jointly provide advanced immunology assay services. This collaboration combines Sai Life Sciences' research capabilities with Mabtech's specialized expertise, creating a comprehensive service offering for clients in the immunology research sector.

The establishment of the Boston facility and the strategic partnership with Mabtech demonstrates Sai Life Sciences' focus on expanding its global footprint and enhancing its research and development capabilities in specialized areas of biotechnology.